Shanghai Allist Pharmaceuticals Co., Ltd.
Research Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) on Bullrun: market cap CNY 36.81B, P/E 13.8, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688578.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 36.81B
- P/E13.8
- Dividend yield1.4%
- Financial periodQ2 2026
- RevenueCNY 1.74B
- Net incomeCNY 904.75M
- Free cash flowCNY 879.66M
- Gross margin94.8%
Valuation Snapshot
latest market cap is CNY 36.81B; P/E is 13.8; dividend yield is 1.4%.
Peer valuation comparison
Latest P/E is 13.77x versus a Healthcare sector median of 21.8x (36.8% below).
Latest dividend yield is 1.42% versus a Healthcare sector median of 2.4% (40.8% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 36.81B | 13.8 | 1.5% | 1.2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.2 CNY, yield 1.4%.
About Shanghai Allist Pharmaceuticals Co., Ltd.
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC.
ETFs that hold Shanghai Allist Pharmaceuticals Co., Ltd.
US-listed ETFs
Shanghai Allist Pharmaceuticals Co., Ltd. is held by 27 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares MSCI Emerging Markets ETF (EEM) | <0.01% | 0.72% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares MSCI ACWI ETF (ACWI) | <0.01% | 0.32% |
| iShares MSCI ACWI ex U.S. ETF (ACWX) | <0.01% | 0.32% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Shanghai Allist Pharmaceuticals Co., Ltd.'s market cap?
Shanghai Allist Pharmaceuticals Co., Ltd.'s market capitalization is CNY 36.81B.
What is Shanghai Allist Pharmaceuticals Co., Ltd.'s P/E ratio?
Shanghai Allist Pharmaceuticals Co., Ltd.'s price-to-earnings (P/E) ratio is 13.8.
Does Shanghai Allist Pharmaceuticals Co., Ltd. pay a dividend?
Shanghai Allist Pharmaceuticals Co., Ltd. has a dividend yield of 1.4%.
What does Shanghai Allist Pharmaceuticals Co., Ltd. do?
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.